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Artesunate v. quinine for severe 
malaria
To the Editor: Severe malaria is a serious and deadly complication 
of Plasmodium falciparum malaria.[1] We searched the literature to 
identify the current most efficacious pharmacotherapy for severe 
malaria. A recent Cochrane meta-analysis[2] compared the efficacy 
of quinine with artesunate for severe malaria. The primary outcome 
was all-cause death. The meta-analysis included 8 trials. Artesunate 
reduced the risk of death both in adults (relative risk (RR) 0.61, 95% 
confidence interval (CI) 0.50 - 0.75; 1 664 participants, 5 trials) and in 
children (RR 0.76, 95% CI 0.65 - 0.90; 5 765 participants, 4 trials). In 
addition, artesunate was less likely to cause hypoglycaemia.[2]
Currently, artesunate is not registered for use in South Africa, 
despite requests to the manufacturer from South African authorities 
since 2007. However, it is available via the Medicines Control Council 
of South Africa on a named patient basis. The Parenteral Artesunate 
Access Programme was launched in South Africa in 2010.[3] The 
access programme is a valiant effort to improve accessibility, but the 
programme remains unfunded. The current financial limitations of 
the access programme prohibit widespread availability of artesunate. 
The SA Malaria Elimination Committee is addressing these 
difficulties with the various stakeholders.
Given the high mortality of severe malaria and the superior safety, 
efficacy, and ease of administration of artesunate, we keenly await 
its availability at all South African hospitals that are likely to admit 
patients with malaria.
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